RecruitingPhase 3NCT04268524

Randomised Clinical Trial for New Treatment Modalities for Cutaneous Leishmaniasis Caused by Leishmania Tropica, in Pakistan

Randomised, Open Label, Multicentre, Non-inferiority Clinical Trial for New Treatment Modalities for Cutaneous Leishmaniasis Caused by Leishmania Tropica, in Pakistan

Sponsor

Medecins Sans Frontieres, Netherlands

Enrollment

832 participants

Start Date

Oct 7, 2022

Study Type

INTERVENTIONAL

Conditions

Old World Cutaneous Leishmaniasis

Summary

randomised control clinical trial to evaluate miltefosine, thermotherapy and the combination miltefosine-thermotherapy are effective, safe and tolerable alternative treatment options to treat cutaneous leishmaniasis caused by L. tropica, in Pakistan compared to the standard of care.

Eligibility

Min Age: 10 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying drug: miltefosine with thermotherapy for people with old world cutaneous leishmaniasis. The study is currently recruiting participants at 2 locations. People eligible for this study include aged 10 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

COMBINATION_PRODUCTdrug: miltefosine with thermotherapy

see previous

Locations(2)

Kuchlak Primary Health Care Centre (MCH)

Kuchlagh, Balochistan, Pakistan

Shaheed Mohtarma Benazir Bhutto General Hospital

Quetta, Balochistan, Pakistan

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04268524